There is no validated dose for the GLOW blend — only constituent figures, read as context.

GLOW peptide dosage in the research context

GLOW peptide dosage cannot be stated as a validated figure, because the blend has never been dosed in a controlled human trial. Any number below is either constituent-level research data or a non-validated community or clinic convention, presented for context only and never as a recommendation.

The constituent research figures span orders of magnitude and routes, which is itself the point: there is no single unit in which a "GLOW dose" could be expressed. GHK-Cu drives fibroblast collagen synthesis in vitro at roughly 10⁻¹² to 10⁻⁹ M — picomolar to nanomolar concentrations in cell culture — and topical cosmetic formulations run about 0.05% to 2% (w/w) ^[1][2]. BPC-157's rodent tissue-repair studies used roughly 10 ng to 10 µg per rat per day intraperitoneally ^[3], and the same Achilles-tendon work tested doses three orders of magnitude apart (10 µg, 10 ng and 10 pg/kg) ^[3], while a first-in-human IV safety pilot used 10 mg then 20 mg in two adults ^[11]. For the thymosin beta-4 family, a human Phase 1 study gave full-length protein intravenously at 42, 140, 420 and 1260 mg, escalating across four dose tiers ^[6].

A commonly cited research-label blend ratio is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial — a supplier labeling convention, not a clinically validated dose. Notice that those milligram figures bear no fixed relationship to the in-vitro concentrations, topical percentages and per-kilogram animal doses above: a vial label is a packaging decision, not a translation of any study. These figures do not combine into a blend dose, and this site does not present them as one. For the regulatory frame around access, see the GLOW legal status and FDA 503A category.

Half-life and what is known about clearance

No pharmacokinetic data exist for the GLOW blend as a unit; combination PK has never been characterized. The constituents differ widely. BPC-157 has a short elimination half-life — under 30 minutes in rats and dogs — with linear kinetics and rapid breakdown to amino acids. The free GHK tripeptide is cleared rapidly by plasma peptidases, while topical GHK-Cu instead forms a dermal copper depot rather than circulating ^[7]. Thymosin beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses in its human Phase 1 study ^[6].

Whether co-formulation alters any constituent's kinetics is unstudied. Three molecules with three clearance profiles, combined in one vial, do not yield a single predictable half-life, and none has been measured for the blend.

GLOW peptide injection: routes studied and the absence of blend pharmacology

Routes for GLOW are constituent routes only. GHK-Cu is predominantly topical — creams, serums, microneedle and liposomal delivery — with rodent intraperitoneal and intranasal systemic studies ^[1][2][7]. BPC-157 has been given intraperitoneally and intramuscularly in animals and intravenously in the 2-subject human pilot ^[3][11]. Thymosin beta-4 has been studied topically and intraperitoneally in animals and intravenously in human Phase 1 ^[5][6].

The GLOW peptide injection question follows from this directly: community GLOW protocols describe subcutaneous injection of the reconstituted blend, but no peer-reviewed pharmacology supports subcutaneous blend dosing. There is no controlled study of an injected three-peptide GLOW combination, so any injection protocol is a community convention without published blend pharmacology behind it.

How do you reconstitute GLOW peptide?

Lyophilized peptide blends are reconstituted with bacteriostatic water and refrigerated; this is general research-handling context, not a dosing instruction. The GLOW blend's stability when co-formulating a copper complex with two peptides is uncharacterized, and bacteriostatic water contains 0.9% benzyl alcohol to inhibit bacterial growth over multiple uses.

How much bacteriostatic water for GLOW peptide?

Reconstitution volume is a research-handling choice that depends on the vial's stated peptide mass and is not a validated dose. No clinical protocol defines a blend concentration, and all such figures are presented as context only.

Stability: the open question of co-formulating copper with peptides

Blend stability is formulation-specific and uncharacterized in the literature. The constituent notes are instructive. The GHK-Cu complex is most stable near pH 5-6.5, and its blue-violet color indicates an intact Cu(II) complex; strong reducing agents and low-pH actives such as ascorbic acid can break it, releasing the copper from the tripeptide and ending the matrix-signaling form that the skin research describes ^[1].

Lyophilized BPC-157 and TB-500 are reconstituted with bacteriostatic water and refrigerated, standard research handling for freeze-dried peptides. The complication is what happens when all three share a vial. Co-formulating a copper complex with two other peptides raises theoretical compatibility questions — copper redox chemistry, pH windows that suit one constituent but not another, and the possibility that the conditions keeping GHK-Cu intact are not the conditions in which the other two peptides are most stable — none of which has been studied for GLOW specifically. This is one more place where reading GLOW as a single product obscures real uncertainty: the chemistry of the mixture is simply not established, and a label cannot stand in for stability data that does not exist. Anyone weighing the GLOW peptide safety research should read the absence of blend stability data as part of that picture.